Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 451

1.

[Impact of minimal residual disease detection after treatment of multiple myeloma].

Szendrei T, Plander M, Szabó Z, Kereskai L, Kajtár B, Papp G, Iványi JL.

Orv Hetil. 2019 Mar;160(13):502-508. doi: 10.1556/650.2019.31353. Hungarian.

PMID:
30907098
2.

Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study).

Szász R, Altai E, Pál K, Dombi P, Iványi J, Jakucs J, Jóni N, Illés Á, Tárkányi I, Szerafin L, Nagy Z, Farkas P, Nagy Á, Piukovics K, Ujj G, Schneider T.

Pathol Oncol Res. 2019 Apr;25(2):535-540. doi: 10.1007/s12253-018-0474-9. Epub 2018 Oct 25.

3.

Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome.

Plander M, Szendrei T, Vadvári Á, Iványi J.

Pathol Oncol Res. 2018 Oct 25. doi: 10.1007/s12253-018-0482-9. [Epub ahead of print] No abstract available.

PMID:
30357751
4.

Vaccine development might be handled more effectively in biotech companies than in academia.

Ivanyi J.

BMJ. 2018 Feb 21;360:k758. doi: 10.1136/bmj.k758. No abstract available.

PMID:
29467160
5.

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).

Schneider T, Rosta A, Losonczy H, Radványi G, Ujj G, Egyed M, Illés Á, Jakucs J, Szerafin L, Gasztonyi Z, Masszi T, Iványi J, Demeter J, Dombi P, Tóth A, Borbényi Z.

Pathol Oncol Res. 2018 Apr;24(2):199-205. doi: 10.1007/s12253-017-0234-2. Epub 2017 Apr 21.

PMID:
28432650
6.

[Treatment outcome of patients with essential thrombocythemia at our department in Hungary].

Iványi JL, Marton É, Plander M, Szendrei T.

Orv Hetil. 2016 Feb 28;157(9):336-41. doi: 10.1556/650.2016.30323. Hungarian.

PMID:
26895801
7.

Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment.

Plander M, Szendrei T, Bodó I, Iványi JL.

Ann Hematol. 2015 Jul;94(7):1257-8. doi: 10.1007/s00277-015-2368-1. Epub 2015 Apr 15. No abstract available.

PMID:
25869030
8.

Significance of antigen and epitope specificity in tuberculosis.

Ivanyi J, Ottenhoff TH.

Front Immunol. 2014 Oct 23;5:524. doi: 10.3389/fimmu.2014.00524. eCollection 2014. No abstract available.

9.

[Changing times - changing diseases. Review of the neuropathological autopsy documentations at the Markusovszky University Teaching Hospital (1964-2014)].

Garzuly F, Schneider F, Iványi JL, Nagy Z, Varga M, Sütő K, Tolvaj B, Kálmán B.

Orv Hetil. 2014 Oct 26;155(43):1722-8. doi: 10.1556/OH.2014.29996. Hungarian.

PMID:
25327462
10.

[To the editors: regarding "Diagnosis and therapy of primary testicular non-Hodgkin lymphoma" by M. Romics et al].

Iványi JL.

Orv Hetil. 2014 Apr 20;155(16):638. Hungarian. No abstract available.

PMID:
24834543
11.

Function and Potentials of M. tuberculosis Epitopes.

Ivanyi J.

Front Immunol. 2014 Mar 24;5:107. doi: 10.3389/fimmu.2014.00107. eCollection 2014. Review.

12.

Could active case finding reduce the transmission of tuberculosis?

Ivanyi J.

Lancet. 2014 Mar 22;383(9922):1035-6. doi: 10.1016/S0140-6736(14)60510-9. No abstract available.

PMID:
24656191
13.

[A forgotten portrait of Markusovszky (Watercolor by Károly Sterio)].

Iványi JL, Plander M.

Orv Hetil. 2013 Oct 6;154(40):1604. Hungarian. No abstract available.

PMID:
24308060
14.

[Treatment outcome in primary testicular non-Hodgkin lymphoma].

Iványi JL, Marton E, Plander M, Engert ZV, Tóth C.

Orv Hetil. 2013 Oct 20;154(42):1666-73. doi: 10.1556/OH.2013.29726. Hungarian.

PMID:
24121219
15.

Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment.

Ivanyi J, Zumla A.

J Infect Dis. 2013 Jul 15;208(2):185-8. doi: 10.1093/infdis/jit153. Epub 2013 Apr 5. No abstract available.

PMID:
23564637
16.

[Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].

Plander M, Skrapits J, Bozsó T, Szendrei T, Iványi JL.

Orv Hetil. 2012 Oct 14;153(41):1622-8. doi: 10.1556/OH.2012.29458. Hungarian.

PMID:
23045312
17.

[Treatment outcome of immune thrombocytopenia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2012 Oct 14;153(41):1613-21. doi: 10.1556/OH.2012.29456. Hungarian.

PMID:
23045311
18.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

PMID:
22011365
19.

Serodiagnosis of tuberculosis: due to shift track.

Ivanyi J.

Tuberculosis (Edinb). 2012 Jan;92(1):31-7. doi: 10.1016/j.tube.2011.09.001. Epub 2011 Sep 17. Review.

PMID:
21930430
20.

Effects of isoflurane on Nfκb p65, Gadd45a and Jnk1 expression in the vital organs of CBA/CA mice.

Kádár B, Gombos K, Szele E, Ember I, Iványi JL, Csejtei R, Pajkos G.

In Vivo. 2011 Mar-Apr;25(2):241-4.

PMID:
21471541
21.

The secret trumps, impelling the pathogenicity of tubercle bacilli.

Cardona PJ, Ivanyi J.

Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 1:14-9. doi: 10.1016/S0213-005X(11)70013-1. Review. Erratum in: Enferm Infecc Microbiol Clin. 2012 Mar;30(3):172.

PMID:
21420562
22.

A novel human IgA monoclonal antibody protects against tuberculosis.

Balu S, Reljic R, Lewis MJ, Pleass RJ, McIntosh R, van Kooten C, van Egmond M, Challacombe S, Woof JM, Ivanyi J.

J Immunol. 2011 Mar 1;186(5):3113-9. doi: 10.4049/jimmunol.1003189. Epub 2011 Jan 21.

23.

[Károly Lechner and his Transylvanian intellectual heritage].

Iványi J.

Orv Hetil. 2009 Oct 18;150(42):1951-5. doi: 10.1556/OH.2009.HO2241. Hungarian. No abstract available.

PMID:
19812015
24.

[Therapeutic management of central nervous system lymphomas in a single hematological institute].

Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C.

Orv Hetil. 2009 Oct 18;150(42):1937-44. doi: 10.1556/OH.2009.28703. Hungarian.

PMID:
19812012
25.

Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles.

Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Iványi J, Schmitz G, Hofstädter F, Schwarz S, Orsó E, Knüchel R, Brockhoff G.

Leukemia. 2009 Nov;23(11):2118-28. doi: 10.1038/leu.2009.145. Epub 2009 Aug 6.

PMID:
19657365
26.

[Manifestations of systemic mycoses and related infections in the central nervous system].

Tahin B, Cooke J, Grasselly M, Iványi JL, Szima B, Bobest M, Ligeti E, Brittig F, Garzuly F, Tóth C.

Orv Hetil. 2009 Jul 19;150(29):1367-74. doi: 10.1556/OH.2009.28657. Hungarian.

PMID:
19581170
27.

Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy.

Buccheri S, Reljic R, Caccamo N, Meraviglia S, Ivanyi J, Salerno A, Dieli F.

Tuberculosis (Edinb). 2009 Jan;89(1):91-4. doi: 10.1016/j.tube.2008.09.001. Epub 2008 Nov 5.

PMID:
18986840
28.

[The psychiatrist Rudolf Fabinyi: the early years of his career].

Iványi J.

Orv Hetil. 2007 Dec 16;148(50):2389-92. Hungarian. No abstract available.

PMID:
18055364
29.

Anti-16-kilodalton mycobacterial protein immunoglobulin m levels in healthy but purified protein derivative-reactive children decrease after chemoprophylaxis.

Sireci G, Dieli F, Di Liberto D, Buccheri S, La Manna MP, Scarpa F, Macaluso P, Romano A, Titone L, Di Carlo P, Singh M, Ivanyi J, Salerno A.

Clin Vaccine Immunol. 2007 Sep;14(9):1231-4. Epub 2007 Jul 11.

30.

[Complex analysis of prognostic factors in chronic lymphocytic leukemia].

Kajtár B, Jáksó P, Kereskai L, Lacza A, Méhes G, Bodnár MA, Dombi JP, Gasztonyi Z, Egyed M, Iványi JL, Kovács G, Marton E, Palaczki A, Petz S, Tóth P, Sziládi E, Losonczy H, Pajor L.

Orv Hetil. 2007 Apr 22;148(16):737-43. Hungarian.

PMID:
17437950
31.

IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice.

Buccheri S, Reljic R, Caccamo N, Ivanyi J, Singh M, Salerno A, Dieli F.

Eur J Immunol. 2007 Mar;37(3):729-37.

32.

[25 years experiences on diabetic ketoacidotic patients].

Dudás M, Barabás Z, Varga R, Iványi J.

Orv Hetil. 2006 Sep 17;147(37):1777-82. Hungarian.

PMID:
17131797
33.

A case for passive immunoprophylaxis against tuberculosis.

Reljic R, Ivanyi J.

Lancet Infect Dis. 2006 Dec;6(12):813-8.

PMID:
17123901
34.

[István Zsakó, psychiatrist and medical historian].

Iványi J.

Orv Hetil. 2006 Aug 27;147(34):1659-61. Hungarian. No abstract available.

PMID:
17017683
35.

gammadelta T cells condition dendritic cells in vivo for priming pulmonary CD8 T cell responses against Mycobacterium tuberculosis.

Caccamo N, Sireci G, Meraviglia S, Dieli F, Ivanyi J, Salerno A.

Eur J Immunol. 2006 Oct;36(10):2681-90.

36.

[Cytogenetic and molecular monitoring of chronic myeloid leukemia].

Kajtár B, Méhes G, Jaksó P, Kereskai L, Iványi JL, Losonczy H, Egyed M, Tóth P, Tóth A, Gasztonyi Z, Dömötör M, Pajor L.

Orv Hetil. 2006 May 28;147(21):963-70. Review. Hungarian.

PMID:
16812971
37.

Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice.

Tjärnlund A, Rodríguez A, Cardona PJ, Guirado E, Ivanyi J, Singh M, Troye-Blomberg M, Fernández C.

Int Immunol. 2006 May;18(5):807-16. Epub 2006 Mar 28.

PMID:
16569672
38.

Mucosal immunotherapy of tuberculosis: is there a value in passive IgA?

Reljic R, Williams A, Ivanyi J.

Tuberculosis (Edinb). 2006 May-Jul;86(3-4):179-90. Epub 2006 Feb 28. Review.

PMID:
16510311
39.

[Kálmán Pándy's years in Transsylvania].

Iványi J.

Orv Hetil. 2006 Jan 15;147(2):87-9. Hungarian. No abstract available.

PMID:
16509218
40.

Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection.

Reljic R, Clark SO, Williams A, Falero-Diaz G, Singh M, Challacombe S, Marsh PD, Ivanyi J.

Clin Exp Immunol. 2006 Mar;143(3):467-73.

41.

T cells at the foot of the mountains: 10 years of EFIS-Tatra Conferences.

Ivanyi J.

Immunol Lett. 2005 Mar 15;97(2):161-3. Epub 2004 Nov 18. No abstract available.

PMID:
15752553
42.

Time course of mycobacterial infection of dendritic cells in the lungs of intranasally infected mice.

Reljic R, Di Sano C, Crawford C, Dieli F, Challacombe S, Ivanyi J.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):81-8. Epub 2004 Dec 23.

PMID:
15687031
43.

Intranasal bacille Calmette-Guerin (BCG) vaccine dosage needs balancing between protection and lung pathology.

Tree JA, Williams A, Clark S, Hall G, Marsh PD, Ivanyi J.

Clin Exp Immunol. 2004 Dec;138(3):405-9.

44.

Reciprocal stimulation of gammadelta T cells and dendritic cells during the anti-mycobacterial immune response.

Dieli F, Caccamo N, Meraviglia S, Ivanyi J, Sireci G, Bonanno CT, Ferlazzo V, La Mendola C, Salerno A.

Eur J Immunol. 2004 Nov;34(11):3227-35.

45.

Characterization of HLA-DR- and TCR-binding residues of an immunodominant and genetically permissive peptide of the 16-kDa protein of Mycobacterium tuberculosis.

Caccamo N, Meraviglia S, La Mendola C, Bosze S, Hudecz F, Ivanyi J, Dieli F, Salerno A.

Eur J Immunol. 2004 Aug;34(8):2220-9.

46.

Increased incidence of monoclonal B-cell infiltrate in chronic myeloproliferative disorders.

Pajor L, Lacza A, Kereskai L, Jáksó P, Egyed M, Iványi JL, Radványi G, Dombi P, Pál K, Losonczy H.

Mod Pathol. 2004 Dec;17(12):1521-30.

47.

Mouse monoclonal IgA binds to the galectin-3/Mac-2 lectin from mouse macrophage cell lines.

Reljic R, Crawford C, Challacombe S, Ivanyi J.

Immunol Lett. 2004 Apr 30;93(1):51-6.

PMID:
15134899
48.

Mouse IgA inhibits cell growth by stimulating tumor necrosis factor-alpha production and apoptosis of macrophage cell lines.

Reljic R, Crawford C, Challacombe S, Ivanyi J.

Int Immunol. 2004 Apr;16(4):607-14.

PMID:
15039391
49.

Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs.

Williams A, Reljic R, Naylor I, Clark SO, Falero-Diaz G, Singh M, Challacombe S, Marsh PD, Ivanyi J.

Immunology. 2004 Mar;111(3):328-33.

50.

Comments from the translator of Hasek's article.

Ivanyi J.

Transplantation. 2003 Nov 27;76(10):1425-6. No abstract available.

PMID:
14657679

Supplemental Content

Loading ...
Support Center